Brentuximab vedotin in combination with chemotherapy for pediatric patients with ALK+ ALCL: results of COG trial ANHL12P1.

导出 OA

翻译打印收藏纠错

第一作者： Eric J,Lowe

第一单位： Department of Pediatric Hematology-Oncology, Children's Hospital of the King's Daughters, Norfolk, VA.

作者： Eric J,Lowe ^[1] ; Anne F,Reilly ^[2] ; Megan S,Lim ^[3] ; Thomas G,Gross ^[4] ; Lauren,Saguilig ^[5] ; Donald A,Barkauskas ^[6] ; Rui,Wu ^[3] ; Sarah,Alexander ^[7] ; Catherine M,Bollard ^[8]

作者单位： Department of Pediatric Hematology-Oncology, Children's Hospital of the King's Daughters, Norfolk, VA. ^[1] Department of Pediatrics, Children's Hospital of Philadelphia, and. ^[2] Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA. ^[3] Center for Cancer and Blood Disorders, Children's Hospital Colorado, University of Colorado School of Medicine, Denver, CO. ^[4] Children's Oncology Group, Monrovia, CA. ^[5] Department of Preventive Medicine, Keck School of Medicine of the University of Southern California, Los Angeles, CA. ^[6] Division of Haematology/Oncology, Hospital for Sick Children, University of Toronto, Toronto, ON, Canada; and. ^[7] Center for Cancer and Immunology Research, Department of Pediatrics, Children's National Hospital and The George Washington University, Washington, DC. ^[8]